Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA hunt for rare brain disease genes begins

NCT ID NCT06647641

Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects DNA from up to 1,000 adults with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), multiple system atrophy (MSA), or related conditions, plus their family members. Researchers will sequence participants' whole genomes to find genetic variants linked to these diseases. The goal is to better understand the genetic roots of these rare neurological disorders.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify new genetic markers linked to these rare brain diseases, paving the way for future treatments.
What could go wrong
This is an observational study, not a treatment trial. It may not directly benefit participants, and findings may take years to translate into therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with PSP, CBD/CBS or MSA

Ages

35 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions. 2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating/referring clinician. 3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results. 4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)/power of attorney (POA), and have read, understood, and completed the informed consent form. 5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys). Exclusion Criteria: 1. Individuals who have received a blood transfusion within the past 3 months. 2. Individuals who have active hematologic malignancies such as lymphoma or leukemia. 3. Individuals who have had a bone marrow transplant within the past 5 years. 4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Corticobasal degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Corticobasal Degeneration corticobasal degeneration disorder corticobasal syndrome familial spontaneous pneumothorax multiple system atrophy Multiple system atrophy (MSA) with orthostatic hypotension multiple system atrophy, cerebellar type multiple system atrophy, parkinsonian type myopathy, lactic acidosis, and sideroblastic anemia progressive supranuclear palsy Shy-Drager Syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Corticobasal degeneration Corticobasal degeneration (CBD) Corticobasal degeneration syndrome Corticobasal syndrome Corticobasal syndrome (CBS) MSA Msa - multiple system atrophy Msa-C Multiple system atrophy Multiple system atrophy (MSA) with orthostatic hypotension Multiple system atrophy - cerebellar subtype (msa-C) Multiple system atrophy - parkinsonian subtype (msa-P) Multiple system atrophy, cerebellar type Multiple system atrophy, parkinsonian type Progressive supranuclear palsy Progressive supranuclear palsy (PSP) PSP PSP - progressive supranuclear palsy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.